First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis

BACKGROUND: Anti-drug antibodies (ADAs) can impact on the efficacy and safety of biologicals, today used to treat several chronic inflammatory conditions. Specific patient groups may be more prone to develop ADAs. Rituximab is routinely used for ANCA-associated vasculitis (AAV) and as off-label ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Faustini, Francesca, Dunn, Nicky, Kharlamova, Nastya, Ryner, Malin, Bruchfeld, Annette, Malmström, Vivianne, Fogdell-Hahn, Anna, Gunnarsson, Iva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361739/
https://www.ncbi.nlm.nih.gov/pubmed/34389040
http://dx.doi.org/10.1186/s13075-021-02589-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361739/
https://www.ncbi.nlm.nih.gov/pubmed/34389040
http://dx.doi.org/10.1186/s13075-021-02589-6

Ejemplares similares